Novakand Pharma AB (FRA:3EE0) Quick Ratio: 10.05 (As of Dec. 2025) — 70% Above Median


What is Novakand Pharma AB Quick Ratio?

Novakand Pharma AB FRA:3EE0 Quick Ratio is 10.05 as of Dec. 2025, which is 70% above its 10-year median of 5.90. The stock has 1 warning sign investors should review. Among 1,412 Biotechnology companies, Novakand Pharma AB ranks better than 78.61% on this metric.

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Novakand Pharma AB's quick ratio for the quarter that ended in Dec. 2025 was 10.05.

Novakand Pharma AB has a quick ratio of 10.05. It generally indicates good short-term financial strength.

The historical rank and industry rank for Novakand Pharma AB's Quick Ratio or its related term are showing as below:

FRA:3EE0' s Quick Ratio Range Over the Past 10 Years
Min: 0.6   Med: 5.9   Max: 10.74
Current: 10.03

During the past 13 years, Novakand Pharma AB's highest Quick Ratio was 10.74. The lowest was 0.60. And the median was 5.90.

FRA:3EE0's Quick Ratio is ranked better than
78.61% of 1412 companies
in the Biotechnology industry
Industry Median: 3.6 vs FRA:3EE0: 10.03

Novakand Pharma AB  (FRA:3EE0) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Novakand Pharma AB Quick Ratio Related Terms


Novakand Pharma AB Quick Ratio Historical Data

* Premium members only.

The historical data trend for Novakand Pharma AB's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novakand Pharma AB Quick Ratio Chart

Novakand Pharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.75 7.19 2.65 10.60 10.05

Novakand Pharma AB Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.60 5.34 8.02 7.34 10.05

FRA:3EE0 vs VRTX, REGN, ALNY: Quick Ratio Comparison

For the Biotechnology subindustry, Novakand Pharma AB's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novakand Pharma AB Quick Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novakand Pharma AB's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Novakand Pharma AB's Quick Ratio falls into.



Novakand Pharma AB Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Novakand Pharma AB's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Quick Ratio (A: Dec. 2025 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(1.538-0)/0.153
=10.05

Novakand Pharma AB's Quick Ratio for the quarter that ended in Dec. 2025 is calculated as

Quick Ratio (Q: Dec. 2025 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(1.538-0)/0.153
=10.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Quick Ratio →
What does a Quick Ratio of 10.05 mean?
Novakand Pharma AB (FRA:3EE0) has a Quick Ratio of 10.05 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Novakand Pharma AB and its competitors. This is 70% above median its historical median of 5.90. Over the past decade, Novakand Pharma AB's Quick Ratio has ranged from 0.60 to 10.74. According to the industry distribution chart, Novakand Pharma AB ranks #302 out of 1412 companies in the Biotechnology industry, placing it in the top 21.4%.
Is Novakand Pharma AB's Quick Ratio too high?
Novakand Pharma AB's current Quick Ratio of 10.05 is 70% above median its 10-year median of 5.90. Over the past 10 years, this metric has ranged from a low of 0.60 to a high of 10.74. The Biotechnology industry median Quick Ratio is 3.60. Novakand Pharma AB's value of 10.05 is 179.2% above this industry median. Based on the distribution chart, Novakand Pharma AB ranks #302 out of 1412 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Novakand Pharma AB's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Novakand Pharma AB ranks #302 out of 1412 companies for Quick Ratio. This places Novakand Pharma AB in the top 21% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Novakand Pharma AB's value of 10.05 is 179.2% above this benchmark. Historically, Novakand Pharma AB's own Quick Ratio has ranged from 0.60 to 10.74 over the past decade. While the company's 10-year median is 5.90 vs. the industry median of 3.60, Novakand Pharma AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novakand Pharma AB's current Quick Ratio of 10.05 is 179.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Novakand Pharma AB and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novakand Pharma AB's current Quick Ratio is 10.05, which is 70% above median its own 10-year median of 5.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novakand Pharma AB stock overvalued right now?
Novakand Pharma AB (FRA:3EE0) has a current Quick Ratio of 10.05. The current Quick Ratio is 10.05, which is 70% above median its 10-year median of 5.90 and 179.2% above the Biotechnology industry median of 3.60. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Novakand Pharma AB (FRA:3EE0), the current Quick Ratio is 10.05 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Novakand Pharma AB Business Description

Address Nanna Svarts vag 4, Solna, SWE, 171 65
Novakand Pharma AB is developing a new class of innovative drugs focusing on inflammatory diseases and cancer. The company is developing a new class of small molecule drugs that control disease promoting immune cells with precision, by targeting the fractalkine axis.